Repligen (NASDAQ: RGEN) reported Q4 EPS of ($0.01), $0.05 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $15.4 million versus the consensus estimate of $14.7 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.